P169 Vitamin D levels are inversely associated with inflammation in pediatric InflammatoryBowel Disease patients

Abstract Background Multiple pathways link Vitamin D status with the risk of development and the clinical course of Inflammatory Bowel Disease (IBD). However, limited studies have been conducted on the relationship between vitamin D and disease activity in IBD, especially in pediatric population and the results have been inconsistent. Moreover Vitamin D metabolites may provide a more precise assessment of sufficiency and mineral metabolism than total 25-hydroxyvitamin-D (25(OH)D). The aim of our study was to evaluate the concentrations of total25(OH)D, 24,25-dihydroxyvitamin D (24,25(OH)2D) and calcitriol (1,25-(OH)2D) to correlate these values with the disease activity markers. Methods We prospectively enrolled all IBD pediatric patients. Total 25(OH)D, 24,25(OH)2D and1,25-(OH)2D levels were measured by enzyme-linked immunosorbent assay (ELISA). In each patient with IBD, the activity scores of disease and the main inflammation markers were correlated to Vitamin D metabolites. We prospectively enrolled all IBD pediatric patients. Total 25(OH)D, 24,25(OH)2D and1,25-(OH)2D levels were measured by enzyme-linked immunosorbent assay (ELISA). In each patient with IBD, the activity scores of disease and the main inflammation markers were correlated to Vitamin D metabolites. Results One hundred twenty three consecutive IBD children were enrolled, 43% with Crohn Disease (CD),55% Ulcerative colitis (UC), 2% indeterminate colitis. No difference in 25(OH)D,24,25(OH)2D and 1,25-(OH)2D levels were found between CD and UC patients. A significant indirect correlation was found between C reactive protein and 1,25-(OH)2D levels in patients with IBD (r=-0.275, p=0.046) and in CD group (r=-0.477, p=0.039). Moreover, in patients with IBD and CD we found a significant indirect correlation between erythrocyte sedimentation rate(ESR) and 25(OH)D (r=-0.212, p=0.024 and and r=-0.282, p=0.047 respectively). Instead, in the UC group we found only a direct correlation for both fibrinogen and ESR with 1,25-(OH)2Dlevels (r=0.407, p 0.028 and r=0.446, p=0.013). Conclusion Our results suggest that both the active form and the total Vitamin D levels are inversely associated with disease activity especially in CD children. Further studies are needed to clarify the role of Vitamin D deficiency as a consequence or a cause of inflammation.

Download Full-text

HUBUNGAN KADAR VITAMIN D SERUM DENGAN KUALITAS HIDUP PADA PASIEN EPILEPSI

Majalah Kedokteran Neurosains Perhimpunan Dokter Spesialis Saraf Indonesia ◽

10.52386/neurona.v35i4.27 ◽

2018 ◽

Vol 35 (4) ◽

Author(s):

Edith Fitriyana Girsang ◽

Aris Catur Bintoro ◽

Dwi Pudjonarko

Keyword(s):

Quality Of Life ◽

Vitamin D ◽

Immunosorbent Assay ◽

Serum Vitamin ◽

Serum Levels ◽

Enzyme Linked Immunosorbent Assay ◽

Epilepsy Patient ◽

Vitamin D Levels ◽

Spearman Test

THE CORRELATION BETWEEN VITAMIN D SERUM LEVELS WITH QUALITY OF LIFE IN EPILEPSY PATIENTABSTRACTIntroduction: Epilepsy affects overall health status and decreases the life quality of epilepsy patient. Seizure frequency, seizure type, daily activity disorder, depression and anxiety also affect the quality of life epilepsy patient. Vitamin D is considered as a neurosteroid modulator of nerve excitability and seizure susceptibility. Studies of vitamin D direct role in epilepsy are limited. Nevertheless, some studies show the role of vitamin D as an anticonvulsant that reduces the incidence of seizures.Aim: To determine the correlation between vitamin D serum levels with quality of life in epilepsy patient.Method: A cross sectional observational study on people with epilepsy in neurology clinic at Dr. Soeselo Hospital, Slawi, Dr Kariadi Hospital, and Tugurejo Hospital, Semarang in July 2017-January 2018. The quality of life was assessed with Quality of Life in Epilepsy 31 (QOLIE-31). Vitamin D serum levels measured using enzyme-linked immunosorbent assay (ELISA) method. Data were analyzed using Spearman test. Results were considered significant if p<0.05.Results: There was no correlation between vitamin D serum levels with quality of life in epilepsy. There was significant correlation between anxiety with quality of life and there were difference between age group with quality of life. Discussion: There was no correlation between serum vitamin D levels and quality of life in epilepsy patient.Keywords: Epilepsy,quality of life epilepsy, vitamin DABSTRAKPendahuluan: Epilepsi mempengaruhi status kesehatan secara keseluruhan dan menurunkan kualitas hidup pasien epilepsi. Frekuensi bangkitan, tipe bangkitan, gangguan aktivitas harian, depresi dan ansietas, juga memengaruhi kualitas hidup pasien epilepsi. Vitamin D dianggap neurosteroid, sebagai modulator eksitabilitas saraf dan kerentanan bangkitan. Bukti langsung untuk peran vitamin D dalam epilepsi terbatas. Namun beberapa penelitian menunjukkan peran vitamin D sebagai antikonvulsan yang mengurangi kejadian bangkitan.Tujuan: Mengetahui hubungan kadar vitamin D serum dengan kualitas hidup pada pasien epilepsi.Metode: Penelitian potong lintang terhadap pasien epilepsi yang berobat ke Poliklinik Saraf RSUD Dr. Soeselo, Slawi, RSUP Dr. Kariadi, Semarang, dan RS Tugurejo, Semarang pada bulan Juli 2017-Januari 2018. Kualitas hidup dinilai menggunakan kuesioner Quality of Life in Epilepsy 31 (QOLIE-31), pengukuran kadar vitamin D serum menggunakan metode enzyme-linked immunosorbent assay (ELISA). Data dianalisis dengan uji Spearman, hasil dianggap bermakna jika p<0,05.Hasil: Tidak didapatkan hubungan antara kadar vitamin D serum dengan kualitas hidup serta domainnya pada pasien epilepsi. Didapatkan hubungan yang bermakna antara ansietas dengan kualitas hidup dan antara kelompok usia dengan kualitas hidup.Diskusi: Tidak terdapat hubungan bermakna antara kadar vitamin D serum dengan kualitas hidup pada pasien epilepsi.Kata kunci: Epilepsi, kualitas hidup, vitamin D

Download Full-text

Association of Fok1 VDR polymorphism with Vitamin D and its associated molecules in pulmonary tuberculosis patients and their household contacts

Scientific Reports ◽

10.1038/s41598-019-51803-8 ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 4

Author(s):

Sudhasini Panda ◽

Ambrish Tiwari ◽

Kalpana Luthra ◽

S. K. Sharma ◽

Archana Singh

Keyword(s):

Vitamin D ◽

Active Form ◽

Enzyme Linked Immunosorbent Assay ◽

Healthy Controls ◽

Vdr Polymorphism ◽

Protein Levels ◽

Household Contacts ◽

Vitamin D Levels ◽

Pcr Rflp ◽

Polymerase Chain

Abstract Status of Fok I VDR polymorphism along with vitamin D, Vitamin D receptor (VDR), and cathelicidin levels in Tuberculosis (TB) patients compared to household contacts and implication of these findings in susceptibility to TB is not known. 150 active TB patients, 150 household contacts and 150 healthy controls were recruited from North Indian population. Fok1 VDR polymorphism was studied by polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP).VDR mRNA and protein levels were studied using quantitative real time PCR (q rt PCR) and enzyme linked immunosorbent assay (ELISA) respectively. Cathelicidin and Vitamin D levels were measured using ELISA and chemiluminescence immunoassay (CLIA) respectively. Significant association was found between Fok1 polymorphism and susceptibility to TB (P < 0.0005). VDR mRNA, VDR protein and vitamin D levels were significantly lower in active TB group when compared to household contacts and healthy controls (P < 0.0001, 0.0001 and 0.0005 respectively). Cathelicidin levels were higher in active TB patients compared to other groups (P < 0.0001). Expression of VDR and cathelicidin was significantly higher among ‘FF’ genotypes of VDR (more active form of VDR) compared to ‘ff’ genotype (less active form of VDR). ‘f’ allele was associated with increased susceptibility to TB. Higher frequency of ‘F’ allele, increased VDR expression along with increased vitamin D levels in household contacts compared to active TB group might be responsible for protection against active TB.

Download Full-text

AB0806 DOES VITAMIN D INFLUENCE THE ACTIVITY OF THE DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS?

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.4625 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1704.1-1705

Author(s):

L. Montolio-Chiva ◽

A. V. Orenes Vera ◽

M. Aguilar-Zamora ◽

C. Vergara-Dangond ◽

I. Vázquez-Gómez ◽

...

Keyword(s):

Vitamin D ◽

Psoriatic Arthritis ◽

Disease Activity ◽

Functional Capacity ◽

Inverse Correlation ◽

Hypovitaminosis D ◽

Joint Involvement ◽

Average Value ◽

Vitamin D Levels

Background:Several studies have shown an inverse relationship between vitamin D levels (25OHD) and disease activity in patients with rheumatoid arthritis (RA). However, the existing data in patients with psoriatic arthritis (PsA) are poor, and they use the DAS28 index as a peripheral joint activity marker by extrapolation with RA.Objectives:To analyze the relationship between 25OHD levels, disease activity and functional capacity in patients with PsA.Methods:Transversal, observational, descriptive study. We included PsA patients with peripheral joint involvement. We collected demographic variables (gender, age), clinical variables [follow-up, received treatments, TJC (68), SJC (68), VAS] and analytical variables (25OHD, CRP, ESR). We usedDisease activity in psoriatic arthritis(DAPSA) score to measure disease activity, and theHealth assessment questionnaire(HAQ) to determine functional capacity. Levels of 25 OHD <20 ng/ml and between 20-30 ng/ml were considered deficient and insufficient, respectively. Statistical analysis was made with SPSS 22.0. The descriptive analysis results were expressed as percentage and mean ± SD. We used Pearson’s correlation to assess the association between quantitative variables and T test to compare means between dichotomous variables.Results:125 patients were included, the majority women (60.8%), with an average age of 55.4 (SD 12.2) years. The average follow-up was 75.5 (SD 68.3) months. 97.6% of patients had received DMARDs and 40.8% biologics, and almost half of the patients (42.7%) took calcium and 25OHD supplements. The average value of 25OHD was 27.1 (SD 12.1) ng/ml, with 30% of patients having 25OHD deficit and 63.3% insufficiency. The majority of patients had an acceptable disease control, with a mean DAPSA of 10.5 (SD 7,9); and mean of CRP, ESR, TJC and SJC was 6.1 (SD 3.7) mg/l, 10.2 (SD 9.9) mm/h, 1.3 (SD 2.5) and 0.7 (SD 2.1), respectively. The average value of HAQ was 0.6 (SD 0.7). We observed an inverse correlation between 25OHD levels and joint counts, TJC (p=0.02) and SJC (p=0.03). On the other hand, patients with hypovitaminosis D presented a tendency to get higher scores in DAPSA index (P=0.07). We do not observe any relationship between 25OHD and HAQ.Conclusion:As can be seen in our sample, low values of 25OHD are related to increased disease activity in patients with PsA.Disclosure of Interests:L Montolio-Chiva: None declared, Ana V Orenes Vera: None declared, Marta Aguilar-Zamora: None declared, C Vergara-Dangond: None declared, I Vázquez-Gómez: None declared, Eduardo Flores: None declared, A Sendra-García: None declared, À Martínez-Ferrer: None declared, Elia Valls-Pascual Grant/research support from: Roche, Novartis, and AbbVie, Speakers bureau: AbbVie, Lilly, Pfizer, MSD, Novartis, Janssen, Bristol Myers Squibb, UCB Pharma, D Ybáñez-García Speakers bureau: Lilly, Roche, Sanofi, V Núñez-Monje: None declared, I Torner-Hernández: None declared, Juanjo J Alegre-Sancho Consultant of: UCB, Roche, Sanofi, Boehringer, Celltrion, Paid instructor for: GSK, Speakers bureau: MSD, GSK, Lilly, Sanofi, Roche, UCB, Actelion, Pfizer, Abbvie, Novartis

Download Full-text

Obesity, oxidative DNA damage and vitamin D as predictors of genomic instability in children and adolescents

International Journal of Obesity ◽

10.1038/s41366-021-00879-2 ◽

2021 ◽

Author(s):

Moonisah Usman ◽

Maria Woloshynowych ◽

Jessica Carrilho Britto ◽

Ivona Bilkevic ◽

Bethany Glassar ◽

...

Keyword(s):

Vitamin D ◽

Dna Damage ◽

Genomic Instability ◽

Oxidative Dna Damage ◽

Nutritional Deficiencies ◽

Aetiological Factor ◽

Enzyme Linked Immunosorbent Assay ◽

Childhood And Adolescence ◽

Paediatric Obesity ◽

Vitamin D Levels

Abstract Background/objectives Epidemiological evidence indicates obesity in childhood and adolescence to be an independent risk factor for cancer and premature mortality in adulthood. Pathological implications from excess adiposity may begin early in life. Obesity is concurrent with a state of chronic inflammation, a well-known aetiological factor for DNA damage. In addition, obesity has been associated with micro-nutritional deficiencies. Vitamin D has attracted attention for its anti-inflammatory properties and role in genomic integrity and stability. The aim of this study was to determine a novel approach for predicting genomic instability via the combined assessment of adiposity, DNA damage, systemic inflammation, and vitamin D status. Subjects/methods We carried out a cross-sectional study with 132 participants, aged 10–18, recruited from schools and paediatric obesity clinics in London. Anthropometric assessments included BMI Z-score, waist and hip circumference, and body fat percentage via bioelectrical impedance. Inflammation and vitamin D levels in saliva were assessed by enzyme-linked immunosorbent assay. Oxidative DNA damage was determined via quantification of 8-hydroxy-2′-deoxyguanosine in urine. Exfoliated cells from the oral cavity were scored for genomic instability via the buccal cytome assay. Results As expected, comparisons between participants with obesity and normal range BMI showed significant differences in anthropometric measures (p < 0.001). Significant differences were also observed in some measures of genomic instability (p < 0.001). When examining relationships between variables for all participants, markers of adiposity positively correlated with acquired oxidative DNA damage (p < 0.01) and genomic instability (p < 0.001), and negatively correlated with vitamin D (p < 0.01). Multiple regression analyses identified obesity (p < 0.001), vitamin D (p < 0.001), and oxidative DNA damage (p < 0.05) as the three significant predictors of genomic instability. Conclusions Obesity, oxidative DNA damage, and vitamin D deficiency are significant predictors of genomic instability. Non-invasive biomonitoring and predictive modelling of genomic instability in young patients with obesity may contribute to the prioritisation and severity of clinical intervention measures.

Download Full-text

The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency

Pharmaceuticals ◽

10.3390/ph14030284 ◽

2021 ◽

Vol 14 (3) ◽

pp. 284

Author(s):

Anna Zielińska ◽

Aleksandra Sobolewska-Włodarczyk ◽

Maria Wiśniewska-Jarosińska ◽

Anita Gąsiorowska ◽

Jakub Fichna ◽

...

Keyword(s):

Vitamin D ◽

Disease Activity ◽

Pain Intensity ◽

Disease Duration ◽

Dietary Habits ◽

Vitamin D Supplementation ◽

Pain Severity ◽

Clinical Activity ◽

Inflammatory Status ◽

Vitamin D Levels

Due to its immunomodulatory effect, vitamin D has been associated with clinical parameters and outcomes in inflammatory bowel diseases (IBDs) which are chronic conditions of the gastrointestinal tract. Upon synthesis or digestion, vitamin D is metabolized in the liver to form 25(OH)D3, the major circulating metabolite. Further renal hydroxylation generates 1,25(OH)2D3, the most potent metabolite. Our aim was to examine the association between vitamin D levels, and its supplementation and pain intensity in 39 IBD patients and 33 healthy individuals. 25(OH)D3 and 1,25(OH)2D3 serum levels were measured. Each subject filled out visual analog scale (VAS) and Laitinen’s pain assessment scales. Laboratory results were obtained, and disease activity was assessed. Linear regression was employed to investigate the correlation between 25(OH)D3, 1,25(OH)2D3 and pain intensity, clinical activity parameters, C-reactive protein, disease duration, and dietary habits. In IBD patients, 25(OH)D3 was increased, whereas 1,25(OH)2D3 was not. Vitamin D3 supplementation did not influence their levels. No correlation was found between pain scores, disease activity, inflammatory status, disease duration or dietary habits and both forms of vitamin D. Elevated 25(OH)D3 and normal 1,25(OH)D3 were found in IBD patients as compared to the controls. We discovered no effect from supplementation and no association between pain severity and vitamin D.

Download Full-text

Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment

Endocrine Reviews ◽

10.1210/er.2016-1070 ◽

2016 ◽

Vol 37 (5) ◽

pp. 521-547 ◽

Cited By ~ 97

Author(s):

Peter J. Tebben ◽

Ravinder J. Singh ◽

Rajiv Kumar

Keyword(s):

Vitamin D ◽

Vitamin D Receptor ◽

Active Form ◽

Elevated Serum ◽

Diagnosis And Treatment ◽

Vitamin D Metabolites ◽

Hydroxyvitamin D ◽

Dihydroxyvitamin D ◽

Stone Formers ◽

25 Hydroxyvitamin D

AbstractHypercalcemia occurs in up to 4% of the population in association with malignancy, primary hyperparathyroidism, ingestion of excessive calcium and/or vitamin D, ectopic production of 1,25-dihydroxyvitamin D [1,25(OH)2D], and impaired degradation of 1,25(OH)2D. The ingestion of excessive amounts of vitamin D3 (or vitamin D2) results in hypercalcemia and hypercalciuria due to the formation of supraphysiological amounts of 25-hydroxyvitamin D [25(OH)D] that bind to the vitamin D receptor, albeit with lower affinity than the active form of the vitamin, 1,25(OH)2D, and the formation of 5,6-trans 25(OH)D, which binds to the vitamin D receptor more tightly than 25(OH)D. In patients with granulomatous disease such as sarcoidosis or tuberculosis and tumors such as lymphomas, hypercalcemia occurs as a result of the activity of ectopic 25(OH)D-1-hydroxylase (CYP27B1) expressed in macrophages or tumor cells and the formation of excessive amounts of 1,25(OH)2D. Recent work has identified a novel cause of non-PTH-mediated hypercalcemia that occurs when the degradation of 1,25(OH)2D is impaired as a result of mutations of the 1,25(OH)2D-24-hydroxylase cytochrome P450 (CYP24A1). Patients with biallelic and, in some instances, monoallelic mutations of the CYP24A1 gene have elevated serum calcium concentrations associated with elevated serum 1,25(OH)2D, suppressed PTH concentrations, hypercalciuria, nephrocalcinosis, nephrolithiasis, and on occasion, reduced bone density. Of interest, first-time calcium renal stone formers have elevated 1,25(OH)2D and evidence of impaired 24-hydroxylase-mediated 1,25(OH)2D degradation. We will describe the biochemical processes associated with the synthesis and degradation of various vitamin D metabolites, the clinical features of the vitamin D-mediated hypercalcemia, their biochemical diagnosis, and treatment.

Download Full-text

Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4

Multiple Sclerosis Journal ◽

10.1177/1352458511424590 ◽

2011 ◽

Vol 18 (5) ◽

pp. 578-586 ◽

Cited By ~ 46

Author(s):

Woojun Kim ◽

Ji-Eun Lee ◽

Xue Feng Li ◽

Su-Hyun Kim ◽

Byeong-Gu Han ◽

...

Keyword(s):

High Risk ◽

Disease Activity ◽

Immunosorbent Assay ◽

Neurological Diseases ◽

Aquaporin 4 ◽

Enzyme Linked Immunosorbent Assay ◽

Specific Marker ◽

Longitudinal Measurement ◽

Longitudinal Measurements ◽

Baculovirus System

Background: Antibodies to aquaporin-4 (AQP4-Ab), known as NMO-IgG, are a sensitive and specific marker for neuromyelitis optica (NMO). Methods: To develop an enzyme-linked immunosorbent assay (ELISA) for AQP4-Ab, we expressed M23 isoform of human AQP4 in a baculovirus system, and used it as an antigen. We measured AQP4-Ab in the sera of 300 individuals: 64 with definite NMO, 31 with high-risk NMO, 105 with multiple sclerosis (MS), 57 with other neurological diseases (ONDs), and 43 healthy controls. We also performed longitudinal measurements of AQP4–Ab in 787 samples collected from 51 patients with definite or high-risk NMO. Results: AQP4-Abs were positive in 72% with definite NMO, 55% with high-risk NMO, and 4% with MS, but none of the OND patients and the healthy individuals. The longitudinal measurement showed AQP4-Ab levels correlating with disease activity. Out of 38 initially seropositive patients, 21 became seronegative under effective immunosuppressive therapy. During most relapses, the serum AQP4-Ab levels were either high or rising compared with the previous value, although rising AQP4-Ab levels did not always lead to acute exacerbation. Two of the 13 initially seronegative patients converted to seropositive following acute exacerbations. Conclusions: We established an AQP4-Ab ELISA, which could be a potential monitoring tool of disease activity.

Download Full-text

POS1067 BASELINE VITAMIN D LEVELS AND DISEASE ACTIVITY AND RESPONSE IN PORTUGUESE PATIENTS WITH PSORIATIC ARTHRITIS UNDER bMDARD: DOES IT MAKE A DIFFERENCE?

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.1255 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 812.1-812

Author(s):

F. Oliveira Pinheiro ◽

B. M. Fernandes ◽

S. Garcia ◽

M. Rato ◽

D. Fonseca ◽

...

Keyword(s):

Vitamin D ◽

Psoriatic Arthritis ◽

Disease Activity ◽

Rheumatic Diseases ◽

Response To Therapy ◽

Response Criteria ◽

National Database ◽

Vitamin D Levels ◽

Activity Measures ◽

Disease Activity Measures

Background:There is growing evidence that vitamin D [25(OH)D]) plays an important role in maintaining skeletal health and modulating the immune system. Epidemiological data indicate that vitamin D deficiency is common in immune-mediated rheumatic diseases, especially in rheumatoid arthritis, but there is little data regarding its association with disease activity and response to therapy in patients with psoriatic arthritis (PsA) under bDMARD therapy.Objectives:We aimed to assess whether 25(OH)D basal levels correlate with disease activity and clinical response to the first bDMARD, at 6 and 12 months of therapy, in a monocentric cohort of patients with PsA.Methods:This retrospective study was carried out on PsA patients from a Rheumatology department of a tertiary hospital, fulfilling CASPAR criteria and registered in our national database (Reuma.pt), who started the first bDMARD since 2008. Demographic, clinical and laboratory criteria were evaluated at 0, 6 and 12 months of biologic therapy. Disease activity was assessed using CDAI, SDAI, DAS28(4V), BASDAI, ASDAS, DAPSA and the response was measured using the EULAR, BASDAI50, ASDAS, ASAS, ACR and PsARC responses. Correlations were made between absolute serum levels of 25(OH)D and continuous variables, as well as associations between different vitamin D cutoffs and disease activity measures and response criteria. Multiple linear and logistic regression analyses were performed to determine whether vitamin D is a predictor of disease activity and therapeutic response.Results:We included 81 patients, 41 (50.6%) females; with a mean age of 48.0±11.7 years, a mean disease duration of 9.5±7.4 years and a mean body mass index of 28.4±5.2 kg/m2. Thirteen (16.0%) were smokers. The mean 25(OH)D basal level was 25.5±13.2 ng/ml, 21 (25.9%) had 25(OH)D basal levels ≥30 ng/mL and 31 (38.3%) ≤20 ng/mL. Sixty-two patients (76.5%) were under csDMARD therapy. Golimumab (29, 35,8%), etanercept (28, 34.6%) and adalimumab (10, 12.3%) were the most frequently prescribed bDMARDs. There were only very weak, albeit positive, correlations between 25(OH)D levels and measures of disease activity. The BASDAI50 response at 6 months was associated with higher basal 25(OH)D levels (29.5±14.5 vs 21.5±10.2 ng/mL, p = 0.013); the ASAS20 (33.9±15.9 vs 24.2±12.8 ng/mL; p = 0.023), ASAS40 (31.9±14.6 vs 25.0±13.8 ng/mL; p = 0.023) and ASAS70 (47.0±4.2 vs 26.6±14.2; p = 0.027) responses at 12 months were associated with higher basal levels of 25(OH)D; basal 25(OH)D levels were ≥ 30ng/mL in a significantly higher proportion of patients who achieved CDAI (38.9% vs 10.5%; p = 0.027) and SDAI (38.9% vs 7.7%; p = 0.008) remission and ASDAS disease inactive (29.4% vs 7.3%; p = 0.040) at 1 year. In the regression models, basal levels of 25(OH)D were found to be predictors of good EULAR responders (OR 1.315, 1.017-1.213 95% CI; p = 0.037) at 6 months. Basal levels of 25(OH)D were not significantly different in patients who discontinued bDMARD and no significant correlations or associations were identified regarding more specific PsA activity measures, such as DAPSA and PsARC, nor were they predictive of these responses.Conclusion:We can conclude that there is a global trend for an association between higher levels of vitamin D and lower measures of disease activity and better therapeutic responses to the first biologic. It was possible to find statistically significant associations with some disease activity measures and response criteria that, although primarily designed for other rheumatic diseases, are often used in PsA.Disclosure of Interests:None declared.

Download Full-text

Evaluation of Vitamin D Metabolism in Patients with Type 1 Diabetes Mellitus in the Setting of Cholecalciferol Treatment

Nutrients ◽

10.3390/nu12123873 ◽

2020 ◽

Vol 12 (12) ◽

pp. 3873

Author(s):

Alexandra Povaliaeva ◽

Ekaterina Pigarova ◽

Artem Zhukov ◽

Viktor Bogdanov ◽

Larisa Dzeranova ◽

...

Keyword(s):

Diabetes Mellitus ◽

Vitamin D ◽

Type 1 Diabetes ◽

Type 1 Diabetes Mellitus ◽

Controlled Study ◽

Affinity Constant ◽

Vitamin D Metabolites ◽

Vitamin D Metabolism ◽

Vitamin D Levels

In this prospective controlled study, we examined 25 adults with adequately controlled (HbA1c level < 8.0%) type 1 diabetes mellitus (T1DM) and 49 conditionally healthy adults, intending to reveal the diversity of vitamin D metabolism in the setting of cholecalciferol intake at a therapeutic dose. All patients received a single dose (150,000 IU) of cholecalciferol aqueous solution orally. Laboratory assessments including serum vitamin D metabolites (25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3-epi-25(OH)D3 and 24,25(OH)2D3), free 25(OH)D, vitamin D-binding protein (DBP) and parathyroid hormone (PTH) as well as serum and urine biochemical parameters were performed before the intake and on Days 1, 3 and 7 after the administration. The studied groups had no significant differences in baseline parameters except that the patients with diabetes showed higher baseline levels of free 25(OH)D (p < 0.05). They also lacked a correlation between the measured and calculated free 25(OH)D in contrast to the patients from the control group (r = 0.41, p > 0.05 vs. r = 0.88, p < 0.05), possibly due to the glycosylation of binding proteins, which affects the affinity constant for 25(OH)D. The elevation of vitamin D levels after the administration of cholecalciferol was comparable in both groups, with slightly higher 25(OH)D3 levels observed in the diabetes group throughout the study since Day 1 (p < 0.05). Overall, our data indicate that in patients with adequately controlled T1DM 25(OH)D3 levels and the therapeutic response to cholecalciferol is similar to that in healthy individuals.

Download Full-text